Document is current
Any future updates will be listed below
-
Authors
Altman, Brian J. https://orcid.org/0000-0002-3954-4916
Lin, Po-Ju
Mattick, Lindsey J.
Outland, Elliot H.
Bautista, Javier
Li, Chin-Shang
Gada, Umang
Morris, Kristina M.
Knudsen-Clark, Amelia M.
Mwangi, Daniel
DeRollo, Rachel E.
Kleckner, Amber S.
Kleckner, Ian R.
Gilmore, Nikesha J.
Esparaz, Benjamin T.
Curtis, Amarinthia
Conlin, Alison
Monaco, Gianni
Hughey, Jacob J.
Mustian, Karen M.
-
Funding
Funding for this research was provided by:
National Cancer Institute (UG1CA189961-07S1, UG1CA189961-07S1, UG1CA189961, UG1CA189961, UG1CA189961, UG1CA189961, UG1CA189961, UG1CA189961, UG1CA189961, UG1CA189961-07S1)
- License Information
-
More Information
Article History
Received: 2 April 2025
Revised: 25 July 2025
Accepted: 19 August 2025
First Online: 3 September 2025
Competing interests
: The authors declare no competing interests.
: The YOCAS-II trial (NCT02613364) including the consent form, all original study procedures, and all procedures associated with this study and use of biological samples, was approved by a central Institutional Review Board (IRB) at the University of Rochester and all IRBs at collaborating sites. All participants provided informed consent which included agreement to provide biological samples to be banked and used for future research. The YOCAS-II trial was approved by the Research Subjects Review Board (RSRB) is the University’s IRB, STUDY00000554, and the BloodCCD research was deemed exempt and approved by the RSRB, STUDY00005516. This study was performed in accordance with the Declaration of Helsinki.
: This manuscript contains no personally identifiable information (PII) or protected health information (PHI).
